




RealRate

# PHARMACEUTICAL 2017

Brooklyn ImmunoTherapeutics Inc.  
Rank 96 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2017

## Brooklyn ImmunoTherapeutics Inc. Rank 96 of 313



The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 556% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -50%, being 367% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	10,662
Cost of Goods Sold	0
Intangible Assets	966
Liabilities, Current	6,643
Liabilities, Non-Current	12
Other Assets	1,966
Other Compr. Net Income	51
Other Expenses	8,170
Other Liabilities	5,972
Other Net Income	-607
Property and Equipment	3,101
Research and Development	0
Revenues	22,312
Selling, General and Administrative Expense	16,458

Output Variable	Value in 1000 USD
Assets	16,695
Liabilities	12,627
Expenses	24,628
Stockholders Equity	4,068
Net Income	-2,923
Comprehensive Net Income	-2,898
Economic Capital Ratio	-50%

